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Zusammenfassung
Hintergrund: Bei Tumorpatienten mit Mangelernährung
kann eine heimparenterale Ernährungstherapie (HPE)
eine Verschlechterung des Erkrankungsverlaufs hinaus-
zögern. Das Risiko-Nutzen-Verhältnis ist durch die Gefahr
einer Komplikation seitens des zentralvenösen Katheters
(ZVK) bestimmt. Wenige Studien, oftmals basierend auf
kleinen Stichproben, haben sich mit dieser Thematik bis-
her beschäftigt. Ziel unserer Studie war es, eine reliable
Bestimmung der Inzidenz von ZVK-Komplikationen in der
täglichen HPE-Patientenversorgung in Deutschland zu er-
mitteln. Patienten und Methoden: Um eine große pro-
spektive Kohorten-Studie realisieren zu können, koope-
rierten wir mit einem deutschlandweit arbeitenden HPE-
Dienstleister. Zwischen dem 1. Juli und dem 30. Novem-
ber 2006 wurden konsekutiv alle volljährigen Patienten
mit mehr als 10 Infusionstagen und keiner HPE in der
Vorgeschichte rekrutiert. Das Follow-up wurde bis ein-
schließlich 31. Januar 2007 durchgeführt. Die Datenerhe-
bung erfolgte durch eine standardisierte Erhebung durch
die Mitarbeiter des Dienstleisters und, um eine zu nie -
drige Melderate auszuschließen, durch vom Versorger
unabhängige Telefoninterviews mit den beteiligten medi-
zinischen Fachkräften. Ergebnisse: 481 Patienten erfüll-
ten die Einschlusskriterien, die eine Gesamtsumme von
31 337 Kathetertagen unter Beobachtung einbrachten. 52
Patienten erlitten insgesamt 63 ZVK-Komplikationen, so
dass eine Inzidenzrate von 2,01 ZVK-Komplikationen pro
1000 Kathetertagen und 1,02 ZVK-Infektionen pro 1000
Kathetertagen ermittelt wurde. Schlussfolgerung: Die
HPE kann mit einer relativ niedrigen Rate an ZVK-Kom-
plikationen verabreicht werden.
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Summary
Background: Home parenteral nutrition (HPN) has been
shown to delay deterioration in cancer patients with mal-
nutrition. Its risk-benefit ratio, however, is determined by
the threat of central venous catheter (CVC) complica-
tions. Only few prospective studies on this subject exist,
most of them based on small samples. The objective of
this study was to provide reliable estimates of incidence
rates of CVC complications in everyday HPN patient care
in Germany. Patients and Methods: Aiming for a large
prospective cohort study, we cooperated with a service
provider caring for HPN patients nationwide. Between
July 1 and November 30, 2006, all consecutive adult
 patients with more than 10 infusion days and no previ-
ous history of HPN were recruited. Follow-up ended on
January 31, 2007. Data were collected in a standardised
way by the provider’s staff. To prevent underreporting,
we used computer-assisted telephone interviews with
medical caregivers as a provider-independent data
source. Results: 481 patients met the inclusion criteria,
contributing a total of 31,337 catheter days. 52 patients
experienced a total of 63 CVC complications, resulting in
an incidence rate of 2.01 CVC complications per 1,000
catheter days including 1.02 CVC infections per 1,000
catheter days. Conclusion: HPN administration can be
safely performed with a relatively low rate of CVC com-
plications. 
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Introduction
Malnutrition is frequently observed in chronic and severe dis-
ease, and is associated with impaired outcome [1–3]. In Ger-
man hospitals, every 4th patient is malnourished. In oncology
departments, malnutrition has been found in 38% of the pa-
tients [4]. The survival of an incurable cancer patient is not
only limited by the tumour itself but also by malnutrition [5].
Home parenteral nutrition (HPN) is widely used to delay or
correct malnutrition both in oncological and non-oncological
patients [6, 7]. Its risk-benefit ratio, however, is related to the
threat of central venous catheter (CVC) complications. 
In the largest European study [8], CVC-related complications
were observed in 25% of all HPN patients with mostly benign
indications and long-term HPN care. 50% of the reported com-
plications were catheter infections, resulting in an incidence of
0.6 infections per 1,000 catheter days. Other international stud-
ies reported CVC complication rates between 0.94 and 5.56 per
1,000 catheter days and catheter infection rates between 0.6 and
5.36 per 1,000 catheter days [9–21]. All these studies had some
methodological limitations, as only few were prospective, and
most were based on small samples of predominantly non-onco-
logical patients from single specialised medical centres.
In May 2007, the Deutsche Gesellschaft für Ernährungsme -
dizin e.V. (DGEM) published guidelines for parenteral nutri-
tion and emphasised the necessity of monitoring the HPN ther-
apy for complications and effectiveness [22]. Unlike in Den-
mark, France, or Scotland, in Germany there is no central sur-
veillance of HPN therapy. HPN is managed by many different
agencies, including therapy-initiating physicians, general practi-
tioners, outpatient nursing services, HPN providers, and the pa-
tients themselves without any central standard. To our knowl-
edge, no large prospective study of the occurrence of CVC-
 related complications in HPN patients in Germany exists.
Therefore, the aim of our study was to provide an estimate of
the incidence of CVC complications in everyday HPN patient
care under the conditions of the German healthcare system.
Patients and Methods
Patients and Data Collection
To achieve a large prospective cohort study, we cooperated with a service
provider caring for HPN patients nationwide (Travacare GmbH, Hall-
bergmoos, Germany). Between July 1 and November 30, 2006, all consec-
utive adult patients of the provider with more than 10 infusion days after
hospital discharge and no previous history of HPN were recruited. There
were no restrictions regarding diagnosis, indication, expected survival, and
planned duration of HPN. Informed consent was signed during the first 10
infusion days at home. A total of 481 patients from 181 centres were in-
cluded (fig. 1). Follow-up lasted until January 31, 2007. The study was ap-
proved by the Ethics Committee of the Medical Faculty of the Ludwig
Maximilians University Munich.
Data were collected during monthly patient visits by the provider’s staff,
using standardised case report forms (CRF) and following standard oper-
ating procedures. Besides providing general demographic data including
age, gender, primary diagnosis, and reason for HPN, patients were intervie-
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wed at each visit regarding abnormalities in appetite, thirst, and excretion
as well as the presence of nausea, vomiting, head- or backache, ascites, or
symptoms of catheter complications (e.g. temperature, fever, shivering, in-
fusion abnormalities, exudation, pain, turgor, redness, bleeding close to the
catheter). In the time between the visits, patients and outpatient nursing
staff could use a memory aid document (‘patient’s passport’) to record ab-
normalities. Entries in these documents were copied to the official CRF
during the next visit. Symptoms indicative of CVC complications were re-
corded by the provider’s staff and corroborated with the patients’ atten-
ding physicians. Complications were recorded as local infection, systemic
infection, CVC obstruction, CVC dislocation, CVC defect, other CVC
complication, and/or CVC removal in consequence of a complication. 
To prevent underreporting, face-to-face data collection was complemented
by a second provider-independent information source. This was established
in form of computer-assisted (and thus highly standardised) telephone in-
terviews (CATI) with patients, outpatient nursing personnel, general practi-
tioners, and therapy-initiating physicians. 70.3% of all patients recruited
gave written consent to these interviews. The interviews were carried out by
a specially trained postgraduate public health student at the Department of
Medical Informatics, Biometry, and Epidemiology (IBE) of the Ludwig
Maximilians University Munich. Contacts with patients and professional
caregivers (outpatient nursing personnel, general practitioners, therapy-ini-
tiating physicians) were attempted (up to 5 times) in the order of patient re-
cruitment after a minimum of 12 therapy days. A second interview was at-
tempted 4 weeks later. Professionals were asked if and when any of the
above CVC complications had occurred and whether the diagnosis was as-
sured. If so, the complication was counted regardless of CRF information
recorded during the patient visits. After HPN termination, telephone inter-
views were performed to investigate the patient’s life-status and the cause
of death in case of fatal outcomes. Patient interviews were used to trigger
additional professional interviews in the case of suspected complications.
To minimise the risk of CVC complications, the provider’s staff educated
patients and outpatient nursing personnel in using a highly structured
manual containing text, pictures, and the manufacturers’ instructions to
illustrate the correct process of preparing the infusion and thus assure
aseptic handling even without the use of gloves and gowns. The following
parameters were considered as potential risk factors for the incidence of
CVC complications: the type of catheter (port system, Broviac/Hickman
catheter, other), the use of an infusion pump, the HPN frequency per
week, the frequency of dressing and needle changes, the caregiver in
charge of dressing and needle changes (patient or a relative, outpatient
nursing service, specialised provider), and the use of the patient’s catheter
for other intravenous therapies beside HPN. To get information about the
effect of the HPN therapy, the infusion regimen, the infusion days per
week, and the weight during the HPN were recorded.
Statistical Analysis
Descriptive statistics were computed for all variables using adequate mea-
sures of location and dispersion. Incidence rates of catheter complications
were expressed as events per 1,000 catheter days with 95% confidence in-
 
Screened patients:
599 
Included patients:
481 
Excluded patients  
(< 11 infusion days): 
118 
No consent for 
telephone interviews: 
143 
Telephone sample:
338 
Patients with telephone interviews 
with doctors and/or nurses: 
195 
Patients without telephone interviews 
with doctors and/or nurses: 
143 
Fig. 1. Methods of
data collection;
flow chart describing
the structure of the
 sample.
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tervals (CI). Exploration of potential risk factors was based on Cox pro-
portional hazards models modelling the time until the patient’s first com-
plication. Analyses were carried out using SAS 9.1 for Linux (SAS Insti-
tute, Cary, NC, USA). 
Results
Patient Characteristics and Data of HPN Use
Between July and November 2006, a total of 481 patients were
recruited, predominantly elderly patients with malignancies
and with port systems (table 1). The majority (98.7%) of port
patients had the port needle changed weekly. Needle changes
were carried out by the provider’s staff in 56.7% of the port
patients, by outpatient nursing personnel in 25.1%, by the at-
tending physician in 16.9%, and by the patient himself or a
relative in 1.3% of the cases. Dressing changes were managed
similarly. 72.8% of the patients had weekly changes, in 40.1%
carried out by the provider’s staff, in 46.6% by outpatient
nursing personnel, in 9.6% by the attending physician, and in
3.7% by the patient or a relative.
In 55.9% of the patients, the CVC was used for HPN only. 376
(78.2%) patients received the HPN 7 days per week, 65
(13.5%) had 5–6, and 38 (7.9%) 1–4 infusions per week. In 
2 (0.4%) patients, data were not available. The daily connect-
ing procedures, including the admixture of vitamins and trace
elements, were carried out by outpatient nursing personnel
(74.4%), the patient or a relative (14.8%), the attending physi-
cian (7.7%), or the provider’s staff (3.1%). The infusion was
administered per gravitational force line (86.5%) or infusion
pump (13.5%). 
Complications
In the course of 31,337 catheter days, 63 CVC complications
were observed in 52 (10.8%) of the 481 patients, leading to 12
catheter removals. Half of the complications (50.8%) were in-
fections, 27.0% systemic (with/without local), and 23.8% local
ones. Furthermore, 17.5% of complications were catheter
 obstructions, 3.2% catheter dislocations, 6.3% other catheter
defects, and 22.2% other complications. So, in total, incidence
of complications was 2.01 per 1,000 catheter days, including
1.02 infections per 1,000 catheter days (table 2). None of the
complications were fatal. Because of the relatively low num-
ber of complications, the exploratory analyses failed to iden -
tify potential risk factors. 
Discussion
The objective of this pilot study was to provide incidence esti-
mates of CVC-related complications in everyday HPN patient
care under the conditions of the German healthcare system.
During the observational period, an incidence of 2.01 CVC-
 related complications per 1,000 catheter days and of 1.02
CVC-related infections were documented. Infections were the
most frequent CVC complications (50.8%), followed by CVC
occlusions (17.5%) and other CVC defects (6.3%).
These figures agree well with results of recently published
studies [8–21] which reported incidences of 0.94–5.56 catheter
complications per 1,000 catheter days and 0.60–5.36 catheter
infections per 1,000 catheter days, but some differences have
to be considered. Most of the previous publications were
based on retrospective data, without a defined observational
plan: only 4 of them [9–12] were prospective studies. They re-
Table 1. Patient characteristics at baseline (n = 481)
Characteristics Mean (range)
Age, years 65 (20–92)
Height, m 168 (125–197)
Weight, kg 58 (25–120)
Body mass index, kg/m2 20.5 (11.8–36.2)
Time since catheter implantation, days 212 (10–2,490)
Duration of HPN, days 65 (11–194)
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
Patients, n (%)
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
Male sex 203 (42.2)
Underlying diagnosis
Cancer 441 (91.7)
Other 20 (4.1)
Not given 20 (4.2)
Indications for HPN
Malabsorption 287 (59.7)
Short bowel syndrome 16 (3.3)
Chronic ileus 4 (0.8)
Other 26 (5.4)
Not given 148 (30.8)
Type of catheter
Port 454 (94.4)
Other 27 (5.6)
HPN = Home parenteral nutrition.
Table 2. Incidence of central venous catheter complications
Patients, n Incidence/1,000 
catheter days 95% CI
Complications 63 2.01 1.55–2.57
Infections
Total 32 1.02 0.70–1.44
Local 15 0.48 0.27–0.79
Systemic 17 0.54 0.32–0.87
Obstructions 11 0.35 0.18–0.63
Dislocations 2 0.06 0.01–0.23
Defects 4 0.13 0.04–0.33
Other 14 0.45 0.24–0.75
Explantationsa 12 0.38 0.20–0.67
a7 due to systemic infection, 2 due to obstruction, 2 due to other compli-
cations, 1 due to local infection and obstruction.
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ported incidences of 0.82–3.86 catheter infections per 1,000
catheter days whereas only one [9] reported an overall inci-
dence of CVC complications (5.56/1,000 catheter days). More-
over, the majority of publications reported on series from sin-
gle centres with specialised expertise in HPN [9–11, 14–18].
They documented the expert standard of specialised centres
that may not be generalisable to the setting of everyday care
provided by general practitioners and unspecialised outpatient
nursing services. Less is known about nationwide care of HPN
patients provided by heterogeneous centres. Ireton-Jones and
DeLegge [19] published more recent US data from 1997–2001
by using the database of one nutrition support provider.
Analysing these data retrospectively, the authors calculated an
incidence of 0.66 catheter infections per 1,000 catheter days
(95% CI 0.59–0.74). Similar results were found by Baxter and
McKee [12] in their audit of the Scottish Home Parenteral
Nutrition Managed Clinical Network (0.9 catheter infections
per 1,000 catheter days; 95% CI 0.45–1.57). 
The underlying disease may affect the incidence of CVC-
 related complications. As shown in some studies [8, 20], the
occurrence of catheter complications was significantly lower in
patients with malignancies than with benign disease. Since our
data are based on a sample of 90.7% patients with malignan-
cies, they should be comparable to those found in studies with
a high percentage of oncological patients. These studies [8, 16,
18, 20] reported CVC-related infections of 0.60–5.36 infections
per 1,000 catheter days, where 3 of them found lower [8, 20] or
similar [18] incidences compared to our estimate of 1.02 infec-
tions per 1,000 catheter days.
Even the type of catheter has been discussed as risk factor for
CVC-related complications. Whereas some studies [10, 20]
found no difference in the incidence of CVC-related infec-
tions between the externally tunnelled type of CVC (Hick-
man/Broviac) and the implanted (Port-a-cath) type, others
reported a significantly lower incidence in patients with
 externally tunnelled systems [8, 16] or with implanted port
catheters [21]. Seeing these heterogeneous results and classify-
ing the very high percentage of port patients in our study
(94.4%) as a German peculiarity, the discussion of this aspect
is quite difficult. Indeed, the incidence of CVC-related infec-
tions found in a sample with 69.27% port patients [16] was
considerable higher than our one. But one of the authors’
main conclusions was that training and experience were likely
to reduce CVC-related infections. So, the lower-risk type of
catheter should not be discussed without including the inten -
sity and quality of education and experience in the daily con-
necting procedure. But even if the occurrence of CVC-related
complications is influenced by a multitude of risk factors, such
as the underlying disease, the type of catheter, education and
experience in the daily connecting procedure, frequency of
 infusions, or use of the catheter for other reasons, in our study
none of these parameters could be identified as an indepen-
dent risk factor.
Despite the fact that, as mentioned above, this trial is a
prospective evaluation with predefined and quality-assured
 investigational instruments, there are still methodological lim-
itations. The restriction to patients with more than 10 infusion
days may have led to overly optimistic incidence estimates.
However, our rationale was to exclude patients with HPN ad-
ministered only during their very last days of life, and for
whom guidelines actually do not recommend HPN [5]. Anoth-
er aspect is that only 70% of the patients gave their consent to
telephone interviews. In 41% of the patients, the attending
physicians and/or nurses actually took part in a telephone
 interview. Complication rates in the group with telephone in-
terviews were higher than in patients without. Possible expla-
nations are false-positive findings due to oversensitivity and
questionable specificity of data collection by telephone (lead-
ing to overestimates), or underreporting of complications in
the non-telephone interview group, or both. 
Nevertheless, this pilot study with its innovative study design
is the first step in the development of further studies that lead
to the implementation and evaluation of quality standards to
maximise excellent patient care and minimise complications
and unnecessary costs in consequence of inadequate medical
and outpatient care and hospital re-admissions [23]. In re-
sponse to the limitations of the present study, further studies
with data collection from patients of multiple HPN service
providers, improved quality control, and 100% corroboration
of suspected cases by means of unstructured expert interviews
are needed. They should describe a reasonable risk-benefit
and cost-benefit ratio in a group of severely ill patients with
advanced cancer in the majority of cases, and be able to estab-
lish a nationwide high-quality standard.
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